# Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

> **NCT04860076** · — · UNKNOWN · sponsor: **Asylia Diagnostics BV** · enrollment: 400 (estimated)

## Conditions studied

- Melanoma
- Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04860076
- **Lead sponsor:** Asylia Diagnostics BV
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-06
- **Primary completion:** 2022-06-06
- **Final completion:** 2023-06-06
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04860076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04860076, "Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04860076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*